Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RCUSthis companyArcus Biosciences, Inc.	$18.72	-7.24×	4.06×	10.36×	-7.31×	-306.1%	96.0%	-156.3%	-142.9%	-55.9%	-41.9%	-18.9%	0.18×	0.33×	-48.25×	4.36×	0.0%	0	-0.28	1	D+
AGIOAgios Pharmaceuticals, Inc.	$30.10	-3.82×	1.32×	29.21×	-3.74×	-87.2%	78.7%	-873.9%	-764.0%	-34.6%	-38.2%	-23.9%	0.03×	0.12×	0×	11.46×	0.0%	3	11.59	2	C
BEAMBeam Therapeutics Inc.	$27.00	-34.22×	2.21×	19.62×	-196.25×	-229.8%	84.0%	-274.6%	-57.2%	-6.5%	-27.4%	-13.1%	0.24×	0.08×	-8.77×	13.09×	0.0%	2	4.01	1	C-
COGTCogent Biosciences, Inc.	$32.94	-17.41×	8.99×	0×	-17.61×	-99.0%	0.0%	0.0%	0.0%	-51.7%	-38.1%	-4.7%	0.4×	0.18×	-108.87×	14.23×	0.0%	2	7.51	1	C-
DNLIDenali Therapeutics Inc.	$20.23	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	3	2.05	2	C
IBRXImmunityBio, Inc.	$7.00	-5.21×	-3.65×	16.08×	-11.68×	-355.9%	99.3%	-226.0%	-310.2%	70.3%	-56.9%	-17.0%	-1.76×	-3.53×	-2.28×	5.1×	0.0%	3	-10.89	2	C
Peer median	—	-5.56×	2.21×	16.08×	-11.68×	-99.0%	78.7%	-226.0%	-57.2%	-34.6%	-38.2%	-14.6%	0.04×	0.12×	-2.28×	11.46×	0.0%	3	4.01	2	—